Peter Goodfellow

Peter Goodfellow, Ph.D., has served as a director since June 2014. Dr. Goodfellow is a scientific consultant for Abingworth, Sanofi, and the Bill and Melinda Gates Foundation.

Dr. Goodfellow was previously the Balfour Professor of Genetics at Cambridge University before working for SmithKline Beecham (later GlaxoSmithKline) as head of research.

He has founded several biotechnology companies and has sat on the boards of Prosensa deCode and several medical charities. Dr. Goodfellow currently serves as the chairman of the board of directors of GammaDelta Therapeutics, a biotech developing novel immunotherapies for cancer and other diseases.

Dr. Goodfellow holds doctorates from Oxford and Bristol Universities.